Therapeutic and routine prophylactic properties of rFactor VIII Fc (efraloctocog alfa, Eloctate®) in hemophilia A
Pratima Chowdary,1 Emma Fosbury,1 Anne Riddell,1 Mary Mathias1,2 1Katharine Dormandy Haemophilia Centre and Thrombosis Unit, Royal Free Hospital, London, UK; 2Haemophilia Centre, Great Ormond Street Hospital for Children, London, UK Abstract: rFVIIIFc (efraloctocog alfa, Eloctate®) is an ex...
Main Authors: | Chowdary P, Fosbury E, Riddell A, Mathias M |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2016-09-01
|
Series: | Journal of Blood Medicine |
Subjects: | |
Online Access: | https://www.dovepress.com/therapeutic-and-routine-prophylactic-properties-of-rfactor-viii-fc-efr-peer-reviewed-article-JBM |
Similar Items
-
Matching-adjusted indirect comparisons of annualized bleeding rate and utilization of BAY 94-9027 versus three recombinant factor VIII agents for prophylaxis in patients with severe hemophilia A
by: Batt K, et al.
Published: (2019-06-01) -
Status of Recombinant Factor VIII Concentrate Treatment for Hemophilia A in Italy: Characteristics and Clinical Benefits
by: Mario Schiavoni, et al.
Published: (2019-12-01) -
Flow-Cytometry Platform for Intracellular Detection of FVIII in Blood Cells: A New Tool to Assess Gene Therapy Efficiency for Hemophilia A
by: Muhammad Elnaggar, et al.
Published: (2020-06-01) -
Spécificité épitopique de la réponse immunitaire humorale non-neutralisante et neutralisante chez l'hémophile A
by: Lebreton, Aurélien
Published: (2012) -
Patient preferences in the treatment of hemophilia A: impact of storage conditions on product choice
by: Tischer B, et al.
Published: (2018-03-01)